PharmaSGP Holding SE/€PSG
05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX
About PharmaSGP Holding SE
PharmaSGP Holding SE operates within the pharmaceutical industry, focusing on the development and commercialization of over-the-counter (OTC) pharmaceutical products. The company's product portfolio includes treatments for chronic conditions, especially in areas such as pain, sexual health, and dermatological issues. Founded in 2012, PharmaSGP is headquartered in Germany and primarily serves the European market. The company distinguishes itself through a targeted approach toward a growing demographic segment of consumers over 50 years of age, leveraging non-chemical and herbal-based remedies to align with current health trends and consumer preferences.
Ticker
€PSG
Sector
Primary listing
XETRA
Industry
Pharmaceuticals
Headquarters
Employees
91
ISIN
DE000A2P4LJ5
Website
PSG Metrics
BasicAdvanced
€327M
16.89
€1.68
-0.04
-
0.18%
Price and volume
Market cap
€327M
Beta
-0.04
52-week high
€29.95
52-week low
€18.97
Average daily volume
3.7K
Financial strength
Current ratio
2.68
Quick ratio
2.089
Long term debt to equity
158.408
Total debt to equity
180.879
Dividend payout ratio (TTM)
82.75%
Interest coverage (TTM)
6.46%
Profitability
EBITDA (TTM)
36.904
Gross margin (TTM)
90.55%
Net profit margin (TTM)
16.14%
Operating margin (TTM)
23.06%
Effective tax rate (TTM)
25.06%
Revenue per employee (TTM)
€1,340,000
Management effectiveness
Return on assets (TTM)
13.58%
Return on equity (TTM)
48.46%
Valuation
Price to earnings (TTM)
16.887
Price to revenue (TTM)
2.725
Price to book
8.92
Price to tangible book (TTM)
-16.2
Price to free cash flow (TTM)
16.117
Free cash flow yield (TTM)
6.20%
Free cash flow per share (TTM)
175.60%
Forward dividend yield
0.18%
Growth
Revenue change (TTM)
13.80%
Earnings per share change (TTM)
11.30%
3-year revenue growth (CAGR)
18.40%
3-year earnings per share growth (CAGR)
21.76%
3-year dividend per share growth (CAGR)
4.26%
Bulls say / Bears say
PharmaSGP Holding SE reported a 17.5% increase in revenues to €118.8 million in 2024, driven by strong organic growth. (finanzwire.com)
The company achieved a 10.8% revenue increase in Q1 2025, reaching €33.5 million, indicating sustained growth momentum. (finanzwire.com)
PharmaSGP's strategic share repurchase of 477,701 shares in October 2024 reflects confidence in its financial health and commitment to shareholder value. (pharmiweb.com)
The reduction of the dividend from €0.51 to €0.05 per share in June 2025 may signal potential cash flow concerns or a shift in capital allocation priorities. (tradingview.com)
FUTRUE GmbH's delisting tender offer at €28 per share in June 2025 introduces uncertainty about the company's future public trading status, potentially affecting investor sentiment. (ainvest.com)
The adjusted EBITDA margin declined from 33.7% in 2023 to 31.3% in 2024, indicating potential challenges in maintaining profitability levels. (finanzwire.com)
Data summarised monthly by Lightyear AI. Last updated on 30 Jun 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for PharmaSGP Holding SE stock?
PharmaSGP Holding SE (PSG) has a market cap of €327M as of July 01, 2025.
What is the P/E ratio for PharmaSGP Holding SE stock?
The price to earnings (P/E) ratio for PharmaSGP Holding SE (PSG) stock is 16.89 as of July 01, 2025.
Does PharmaSGP Holding SE stock pay dividends?
No, PharmaSGP Holding SE (PSG) stock does not pay dividends to its shareholders as of July 01, 2025.
When is the next PharmaSGP Holding SE dividend payment date?
PharmaSGP Holding SE (PSG) stock does not pay dividends to its shareholders.
What is the beta indicator for PharmaSGP Holding SE?
PharmaSGP Holding SE (PSG) has a beta rating of -0.04. This means that it has an inverse relation to market volatility.